open access

Vol 9, No 6 (2013)
Research paper
Published online: 2014-01-28
Get Citation

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) — clinical features, diagnosis, and treatment in the experience from a single institution

Łukasz Targoński, Dorota Kwapisz, Grzegorz Rymkiewicz, Jan Walewski
Onkol. Prak. Klin 2013;9(6):230-238.

open access

Vol 9, No 6 (2013)
ORIGINAL ARTICLES
Published online: 2014-01-28

Abstract

Introduction. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is rarely diagnosed proliferative disease with very poor prognosis originating from the precursors of plasmacytoid dendritic cells.

Materials and methods. In this study, we report on 7 patients diagnosed and treated at our institution between 2006 and 2012. Median age of patients was 68 years (range 37–78 years), and 4 were men. All patients presented with a skin lesion, with additional secondary lymph nodes (n = 3), peripheral blood (n = 1) and bone marrow involvement (n = 3). Disease was diagnosed based on typical immunophenotypical features in histopathological and flow cytometry examination of skin, blood or bone marrow (CD 4+/CD56+: n = 7, CD 123+: n = 3).

Results. Three patients were initially diagnosed with melanoma. Three of patients were treated with non-Hodgkin lymphoma-directed chemotherapy, three other — acute myeloid leukemia chemotherapy and one with acute lymphoblastic leukemia-type treatment. Median overall survival of non transplanted patients (n = 6) was 3.5 months (range 1.5–20 months), while patient allografted from related donor, treated with acute lymphoblastic leukemia-type chemotherapy, remains in complete remission until now (OS = 80 months).

Conclusion. This rare entity is a diagnostic challenge and needs dedicated clinical studies to establish appropriate therapy. Of note is a good outcome of a single patient after allogeneic stem cell transplantation.

Abstract

Introduction. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is rarely diagnosed proliferative disease with very poor prognosis originating from the precursors of plasmacytoid dendritic cells.

Materials and methods. In this study, we report on 7 patients diagnosed and treated at our institution between 2006 and 2012. Median age of patients was 68 years (range 37–78 years), and 4 were men. All patients presented with a skin lesion, with additional secondary lymph nodes (n = 3), peripheral blood (n = 1) and bone marrow involvement (n = 3). Disease was diagnosed based on typical immunophenotypical features in histopathological and flow cytometry examination of skin, blood or bone marrow (CD 4+/CD56+: n = 7, CD 123+: n = 3).

Results. Three patients were initially diagnosed with melanoma. Three of patients were treated with non-Hodgkin lymphoma-directed chemotherapy, three other — acute myeloid leukemia chemotherapy and one with acute lymphoblastic leukemia-type treatment. Median overall survival of non transplanted patients (n = 6) was 3.5 months (range 1.5–20 months), while patient allografted from related donor, treated with acute lymphoblastic leukemia-type chemotherapy, remains in complete remission until now (OS = 80 months).

Conclusion. This rare entity is a diagnostic challenge and needs dedicated clinical studies to establish appropriate therapy. Of note is a good outcome of a single patient after allogeneic stem cell transplantation.

Get Citation

Keywords

blastic plasmacytoid dendritic cell neoplasm, BPDCN, case series, cutaneous involvement, SCT

About this article
Title

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) — clinical features, diagnosis, and treatment in the experience from a single institution

Journal

Oncology in Clinical Practice

Issue

Vol 9, No 6 (2013)

Article type

Research paper

Pages

230-238

Published online

2014-01-28

Bibliographic record

Onkol. Prak. Klin 2013;9(6):230-238.

Keywords

blastic plasmacytoid dendritic cell neoplasm
BPDCN
case series
cutaneous involvement
SCT

Authors

Łukasz Targoński
Dorota Kwapisz
Grzegorz Rymkiewicz
Jan Walewski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl